Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.

The revisions signal a shift toward looking at MS more as a biologically based disease, noted Xavier Montalban, MD, PhD, of ...

Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a ...

Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for ...

Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option ...

The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...

This summary highlights major health news, including EU's endorsement of Novo Nordisk's Wegovy for heart conditions in ...

Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous ...

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

The latest health news covers the European Medicines Agency's approval of Novo Nordisk's Wegovy for heart conditions linked ...